Vascular development and disorders: Molecular analysis and pathogenic insights

Kidney International

Volumn 53, Issue 6, 1998, Pages 1519-1549

  Carmeliet, Peter ^a,b   Collen, Désiré ^a  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Angiogenesis; Atherosclerosis; Blood vessel; Coagulation; Gene therapy; Pericyte; Plasminogen; Restenosis

Indexed keywords

PLASMINOGEN;

ANGIOGENESIS; ATHEROSCLEROSIS; BLOOD CLOTTING DISORDER; CONFERENCE PAPER; GENE THERAPY; HUMAN; HUMAN CELL; PERICYTE; PRIORITY JOURNAL; RESTENOSIS; VASCULAR DISEASE;

EID: 0031780324     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1998.00936.x     Document Type: Conference Paper

References (392)

1. WILTING J, CHRIST B: Embryonic angiogenesis: A review. Naturwissenschaften 83:153-164, 1996
2. RISAU W: Mechanisms of angiogenesis. Nature 386:671-674, 1997
3. FOLKMAN J, D'AMORE PA: Blood vessel formation: What is its molecular basis? (comment) Cell 87;1153-5, 1996
4. BECK L, D'AMORE P: Vascular development: Cellular and molecular recognition. FASEB J 11:365-373, 1997
5. CARMELIET P, COLLEN D: Genetic analysis of blood vessel formation. Role of endothelial versus smooth muscle cells. Trends Cardiovasc Med 7:271-281, 1997
6. NODEN DM: Embryonic origins and assembly of blood vessels. Ann Rev Respir Dis 140:1097-1103, 1989
7. FLAMME I, RISAU W: Induction of vasculogenesis and hematopoiesis in vitro. Development 116:435-439, 1992
8. CARMELIET P, FERREIRA V, BREIFR G, ET AL: Abnormal blood vessel development and lethality in embryos lacking a single vascular endothelial growth factor allele. Nature 380:435-439, 1996
9. FERRARA N, CARMR MOORE K, CHEN H, ET AL: Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380:439-442, 1996
10. GEORGE EL, GEORGES LABOUESSE EN, PATEL KING RS, RAYBURN H, HYNES RO: Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development 119:1079-1091, 1993
11. YANG JT, RAYBURN H, HYNES RO: Embryonic mesodermal defects in alpha 5 integrin-deficient mice. Development 119:1093-1105, 1993
12. VITTET D, BUCHOU T, SCHWEITZER A, DEJANA E, HUBER P: Targeted null-mutation in the vascular endothelial-cadherin gene impairs the organization of vascular-like structures in embryoid bodies. Proc Natl Acad Sci USA 94:6273-6278, 1997
13. DICKSON MC, MARTIN JS, COUSINS FM, KULKARNI AB, KARLSSON S, AKHURST RJ: Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development 121:1845-1854, 1995
14. SHALABY F, ROSSANT J, YAMAGUCHI TP, ET AL: Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376:62-66, 1995
15. FONG GH, ROSSANT J, GERTSENSTEIN M, BREITMAN ML: Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376:66-70, 1995
16. 3, prevents maturation of blood vessels during embryonic neovascularization. J Cell Sci 108:2655-2661, 1995
17. PATAN S, HAENNI B, BURRI PH: Implementation of intussusceptive microvascular growth in the chicken chorioallantoic membrane (CAM): 1. pillar formation by folding of the capillary wall. Microvasc Res 51:80-98, 1996
18. PATAN S, ALVAREZ MJ, SCHITTNY JC, BURRI PH: Intussusceptive microvascular growth: A common alternative to endothelial sprouting. Arch Histol Cytol 55:65-75, 1992
19. PATAN S, HAENNI B, BURRI PH: Implementation of intussusceptive microvascular growth in the chicken chorio-allantoic membrane (CAM). 2. Pillar formation by capillary fusion. Microvasc Res 53:33-52, 1997
20. WILTING J, BIRKENHAGER R, EICHMANN A, ET AL: VEGF121 induces proliferation of vascular endothelial cells and expression of flk-1 without affecting lymphatic vessels of chorioallantoic membrane. Dev Biol 176:76-85, 1996
21. SATO TN, TOZAWA Y, DEUTSCH U, ET AL: Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 376:70-74, 1995
22. PURI MC, ROSSANT J, ALITALO K, BERNSTEIN A, PARTANEN J: The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. EMBO J 14:5884-91, 1995
23. SURI C, JONES PF, PATAN S, ET AL: Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87:1171-80, 1996
24. MAISONPIERRE PC, SURI C, JONES PF, ET AL: Angiopoeitin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277:55-60, 1997
25. PATAN S: TIE1 and TIE2 receptor tyrosine kinases inversely regulate embryonic angiogenesis by the mechanism of intussusceptive microvascular growth. (submitted for publication)
26. NEHLS V, DRENCKHAHN D: The versatility of microvascular pericytes: From mesenchyme to smooth muscle? Histochemistry 99:1-12,1993
27. CARMELIET P, COLLEN D: Gene manipulation and transfer of the plasminogen system and coagulation system in mice. Semin Thromb Hemost 22:525-542, 1996
28. GURTNER GC, DAVIS V, LI H, MCCOY MJ, SHARPE A, CYBULSKY MI: Targeted disruption of the murine VCAM1 gene: Essential role of VCAM-1 in chorioallantoic fusion and placentation. Genes Dev 9:1-14, 1995
29. KWEE L, BALDWIN S, SHEN HM, STEWART CL, BUCK C, LABOW MA: Defective development of the embryonic and extraembryonic circulatory system in vascular cell adhesion molecule (VCAM-1) deficient mice. Development 121:489-503, 1995
30. YANG JT, RAYBURN H, HYNES RO: Cell adhesion events mediated by alpha 4 integrins are essential in placental and cardiac development. Development 121:549-560, 1995
31. CARMELIET P, MACKMAN N, MOONS L, ET AL: Role of tissue factor in embryonic blood vessel development. Nature 383:73-75, 1996
32. LEVÉEN P, PEKNY M, GEBRE MEDHIN S, SWOLIN B, LARSSON E, BETSHOLTZ C: Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities. Genes Dev 8:1875-1887, 1994
33. LINDAHL P, JOHANSSON BR, LEVÉEN P, BETSHOLTZ C: Pericyte loss and microaneurysm formation in PDGF-BB deficient mice. Science 277:242-245, 1997
34. ZHENG X, SAUNDERS TL, CAMPER SA, SAMUELSON LC, GINSBURG D: Vitronectin is not essential for normal mammalian development and fertility. Proc Natl Acad Sci USA 92:12426-12430, 1995
35. MALTEPE E, SCHMIDT JV, BAUNOCH D, BRADFIELD CA, SIMON CM: Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature 386:403-407, 1997
36. KOZAK KR, ABBOTT B, HANKINSON O: ARNT-deficient mice and placental differentiation. Develop Biol 191:247-306, 1997
37. GNARRA JR, WARD JM, PORTER FD, ET AL: Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci USA 94:9102-9107, 1997
38. ROBERT B, ST JOHN PL, HYINK DP, ABRAHAMS DR: Evidence that embryonic kidney cells expressing flk-1 are intrinsic, vasculogenic angioblasts. Am J Physiol 271:F744-F753, 1996
39. BENJAMIN LA, KESHET E: Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci USA 94:8761-8766, 1997
40. ALON T, HEMO I, ITIN A. PE'ER J, STONE J, KESHET E: Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nature Med 1:1024-1028, 1995
41. LANG R, LUSTIG M, FRANCOIS F, SELLINGER M, PLESKEN H: Apoptosis during macrophage-dependent ocular tissue remodelling. Development 120:3395-3403, 1994
42. LANG RA, BISHOP JM: Macrophages are required for cell death and tissue remodeling in the developing mouse eye. Cell 74:453-462, 1993
43. MEESON A, PALMER M, CALFON M, LANG R: A relationship between apoptosis and flow during programmed capillary regression is revealed by vital analysis. Development 122:3929-3938, 1996
44. HANAHAN D: Signaling vascular morphogenesis and maintenance. Science 277:48-50, 1997
45. BROOKS PC, MONTGOMERY AM, ROSENFELD M, ET AL: Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157-1164, 1994
46. RISAU W: Differentiation of endothelium. FASEB J 9:926-933, 1995
47. TOMANEK RJ: Formation of the coronary vasculature: A brief review. Cardiovasc Res 31:E46-E51, 1996
48. TOMANEK RJ, HAUNG L, SUVARNA PR, O'BRIEN LC, RATAJSKA A, SANDRA A: Coronary vascularizution during development in the rat and its relationship to basic fibroblast growth factor. Cardiovasc Res 31:E116-E126, 1996
49. STONE J, ITIN A, ALON T, ET AL: Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 15:4738-4747, 1995
50. FOLKMAN J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1:27-31, 1995
51. FOLKMAN J: Clinical applications of research on angiogenesis. N Engl J Med 333:1757-1763, 1995
52. BATTEGAY EJ: Angiogenesis: Mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med 73:333-346, 1995
53. HANAHAN D, FOLKMAN J: Patterns and emergin mechanisms of the angiogenic switch during tumorigensis. Cell 86:353-364, 1996
54. DOR Y, KESHET E: Ischemia-driven angiogenesis. Trends Cardiovasc Med 7:289-294, 1997
55. KLAGSBRUN M, D'AMORE PA: Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev 7:259-270, 1996
56. FERRARA N, DAVIS-SMYTH T: The biology of vascular endothelial growth factor. Endocrine Rev 18:4-25, 1997
57. SCHAPER W: Collateral vessel growth in the human heart. Role of fibroblast growth factor-2 [editorial; comment]. Circulation 94:600-601, 1996
58. WARE JA, SIMONS M: Angiogenesis in ischemic heart disease. Nature Med 3:158-163, 1997
59. HUDLICKA O, BROWN MD: Postnatal growth of the heart and its blood vessels. J Vasc Res 33:266-287, 1996
60. MUROHARA T, ASAHARA A, SILVER M, ET AL: Essential role of endothelial nitric oxyde synthase in angiogenesis in vivo. (abstract) Circulation 96:I-550, 1997
61. AUERBACH W, AUERBACH R: Angiogenesis inhibition: A review. Pharmac Ther 63:265-311, 1994
62. MCREILLY MS, HOLMGREN L, SHING Y, ET AL: Angiostatin: A novel angiogenesis inhibitor that mediates the suppresion of metastases by a Lewis lung carcinoma. Cell 79:315-328, 1994
63. MCREILLY MS, BOEHM T, SHING Y, ET AL: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285, 1997
64. CARMELIET P, COLLEN D: Gene manipulation of the plasminogen and coagulation system in mice. Semin Thromb Hemost 22:525-542, 1996
65. ASAHARA T, MUROHARA T, SULLIVAN A, ET AL: Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964-967, 1997
66. SUNDERKOTTER C, STEINBRINK K, GOEBELLER M, BHARDWAJ R, SORG C: Macrophages and angiogenesis. J Leukoc Biol 55:410-422, 1994
67. WEIHRAUCHI D, ARRAS M, ZIMMERMANN R, SCHAPER J: Importance of monocytes/macrophages and fibroblasts for healing of micronecroses in porcine myocardium. Mol Cell Biochem 147:13-19, 1995
68. VASSALLI JD: The urokinase receptor. Fibrinolysis 8:172-181, 1994
69. MIGNATTI P, RIFKIN DB: Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein 49:117-137, 1996
70. NUNES I, MUNGER JS, HARPEL JG, ET AL: Structure and activation of the large latent transforming growth factor-beta complex. Int J Obes Relat Metab Disord 20(Suppl 3):S4-S8, 1996
71. SAKSELA O, RIFKIN D: Cell-associated plasminogen activation: Regulation and physiological function. Annu Rev Cell Biol 4:93-126, 1988
72. KFYT BA, BERLEAU LT, NGUYEN HV, WT AL: The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem 271:7788-7795, 1996
73. MARTIN TJ, ALLAN EH, FUKUMOTO S: The plasminogen activator and inhibitor system in bone remodelling. Growth Regul 3:209-214, 1993
74. DONG Z, KUMAR R, YANG X, FIDLER IJ: Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 88:801-810, 1997
75. STATHAKIS P, FITZGERALD M, MATTHIAS LJ, CHESTERMAN CN, HOOG PJ: Generation of angiostatin by reduction and proteolysis by plasmin. Catalysis by a plasmin reductase secreted by cultured cells. J Biol Chem 272:20641-20645, 1997
76. KUBIK S, MANESTAR M: Anatomy of the Lymph Capillaries and Pre-Collectors of the Skin. Stuttgart, Thieme, 1985
77. RHODIN JAG: The Lymphatic System. New York, Oxford University Press, 1974
78. AUKLAND K, REED RK: Interstitial-lymphatic mechanisms in the control of extracellular volume. Physiol Rev 73:1-78, 1993
79. FERGUSON MK, DEFILIPPI VJ, REEDER LB: Characterization of contractile properties of porcine mesenteric and tracheobronchial lymphatic smooth muscle. Lymphology 27:71-81, 1994
80. KAIPAINEN A, KORHONEN J, MUSTONEN T, ET AL: Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA 92:3566-3570, 1995
81. SABIN FR: Am J Anat 9:43-91, 1909
82. HOBSON B, DENEKAMP J: Endothelial proliferation in tumours and normal tissues: Continuous labelling studies. Br J Cancer 49:405-413, 1984
83. VAN DER PUTTE SCJ: Adv Anat Embryol Cell Biol 51:3-60, 1975
84. YOFFEY JM, COURTICE FC: London, Academic Press, 1970
85. BREIER G, CLAUSS M, RISAU W: Coordinate expression of vascular endothelial growth factor receptor-1 (flt-1) and its ligand suggests a paracrine regulation of murine vascular development. Dev Dyn 204:228-239, 1995
86. DUMONT DJ, FONG GH, PURI MC, GRADWOHL G, ALITALO K, BREITMAN ML: Vascularization of the mouse embryo: A study of flk-1, tek, tie, and vascular endothelial growth factor expression during development. Dev Dyn 203:80-92, 1995
87. TERMAN BI, DOUGHER VERMAZEN M: Biological properties of VEGF/VPF receptors. Cancer Metastasis Rev 15:159-163, 1996
88. DVORAK HF, BROWN LF, DETMAR M, DVORAK AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146:1029-1039, 1995
89. FLAMME I, VON REUTERN M, DREXLER HC, SYED ALI S, RISAU W: Overexpression of vascular endothelial growth factor in the avian embryo induces hypervascularization and increased vascular permeability without alterations of embryonic pattern formation. Dev Biol 171:399-414, 1995
90. DRAKE CJ, LITTLE CD: Exogenous vascular endothelial growth factor induces malformed and hyperfused vessels during embryonic neovascularization. Proc Natl Acad Sci USA 42:7657-7661, 1995
91. NEUFELD G, COHEN T, GITAY GOREN H, ET AL: Similarities and differences between the vascular endothelial growth factor (VEGF) splice variants. Cancer Metastasis Rev 15:153-158, 1996
92. BASIC M, EDWARDS NA, MERRILL MJ: Differential expression of vascular endothelial growth factor (vascular permeability factor) forms in rat tissues. Growth Factors 12:11-15, 1995
93. BROOKS PC, STROMBLAD S, SANDERS LC, ET AL: Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 85:683-693, 1996
94. STEFANSSON S, LAWRENCE DA: The serpin PAI-1 inhibits cell migration by blocking integrin alpha v beta 3 binding to vitronectin. Nature 383:441-443, 1996
95. REINARTZ J, SCHAFER B, BATRIA R, KLEIN CE, KRAMER MD: Plasmin abrogates avβ5-mediated adhesion of a human keratinocyte line (HaCat). Exp Cell Res 214:486-498, 1995
96. WEI Y, LUKASHEV M, SIMON DI, ET AL: Regulation of integrin function by the urokinase receptor. Science 273:1551-1555, 1996
97. DENG G, CURRIDEN SA, WANG S, ROSENBERG S, LOSKUTOFF DJ: Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated adhesion and release? J Cell Biol 134:1563-1571, 1996
98. 3: Angiogenesis and apoptosis. Cell Adhesion Commun 3:367-374, 1995
99. FRIEDLANDER M, BROOKS PC, SHAFFER RW, KINCAID CM, VARNER JA, CHERESH DA: Definition of two angiogenic pathways by distinct alpha v integrins. Science 270;1500-1502, 1995
100. 3 integrin, osteopontin, and thrombin. Am J Pathol 149:293-305, 1996
101. PEPPER MS, MEDA P: Basic fibroblast growth factor increases junctional communication and connexin 43 expression in microvascular endothelial cells. J Cell Physiol 153:196-205, 1992
102. ROBERTS WG, PALADE GE: Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 108:2369-2379, 1995
103. DVORAK AM, KOHN S, MORGAN ES, FOX P, NAGY JA, DVORAK HF: The vesiculo-vacuolar organelle (VVO)-A distinct endothelial cell structure that provides a transcellular pathway for macromolecular extravasation. Leuk Biol 59: 100-115, 1996
104. CLAUSS M, GERLACH M, GERLACH H, ET AL: A tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 172:1535-1545, 1990
105. SATO Y, ASADA Y, MARUTSUKA K, HATAKEYAMA K, SUMIYOSHI A: Tissue factor induces migration of cultured aortic smooth muscle cells. Thromb Haemost 75:389-392, 1996
106. COUGHLIN SR: Molecular mechanisms of thrombin signaling. Semin Hematol 31:270-277, 1994
107. ZHANG Y, DENG Y, LUTHER T, ET AL: Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 94:1320-1327, 1994
108. ZHANG Y, DENG Y, LILIENSIEK B, ET AL: Intravenous somatic gene transfer with antisense tissue factor restores blood flow by reducing tumor necrosis factor-induced tissue factor expression and fibrin deposition in mouse Meth-A sarcomas. J Clin Invest 97:2213-2224, 1996
109. MELDER RJ, KOENIG GC, WITWER BP, SAFABAKHSH N, MUNN LL, JAIN RK: During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. (see comments) Nature Med 2:992-997, 1996
110. DEJANA E: Endothelial adherens junctions: Implications in the control of vascular permeability and angiogenesis. J Clin Invest 98:1949-1953, 1996
111. CLAUSS M, WEICH H, BREIER G, ET AL: The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem 271:17629-17634, 1996
112. BARLEON B, SOZZANI S, ZHOU D, WEICH HA, MANTOVANI A, MARME D: Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 87:3336-3343, 1996
113. GROSSKREUTZ CL, ANAND-APTE B, TERMAN B, QUINN TP, D'AMORE PA: Vascular endothelial growth factor (VEGF) is a chemoattractant for vascular smooth muscle cells (SMC). Invest Opthalmol Vis Sci 37:5470-5475, 1996
114. TAKAGI H, KING GL, AIELLO LP: Identification and characterization of vascular endothelial growth factor receptor (Flt) in bovine retinal pericytes. Diabetes 45:1016-1023, 1996
115. NOMURA M, YAMAGISHI S, HARADA S, ET AL: Possible participation of autocrine and paracrine vascular endothelial gorwth factors in hypoxia-induced proliferation of endothelial cells and pericytes. J Biol Chem 270:28316-28324, 1995
116. BANAI S, JAKLITSCH MT, SHOU M, ET AL: Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 89:2183-2189, 1994
117. HARIAWALA MD, HOROWITZ JJ, ESAKOF D, ET AL: VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts. J Surg Res 63:77-82, 1996
118. VAN DER ZEE R, MUROHARA T, LUO Z, ET AL: Vascular endothelial growth factor/Vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. Circulation 95:1030-1037, 1997
119. JING-SHAN H, HASTINGS GA, CHERRY S, GENTZ R, RUBEN S, COLEMAN TA: A novel regulatory function of proteolytically cleaved VEGF-2 for vascular endothelial and smooth muscle cells. FASEB J 11:498-504, 1997
120. KATOH O, TAUCHI H, KAWAISHI K, KIMURA A, SATOW Y: Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res 55: 5687-5692, 1995
121. BROXMEYER HE, COOPER S, LI ZH, ET AL: Myeloid progenitor cells regulatory effects of vascular endothelial growth factor. Int J Hematol 62:203-215, 1995
122. GABRILOVICH DI, CHEN HL, GIRGIS KR, ET AL: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature Med 2:1096-1103, 1996
123. WALTENBERGER J: Modulation of growth factor action. Implications for treatment of cardiovascular diseases. Circulation (in press)
124. STAVRI GT, ZACHARY IC, BASKERVILLE PA, MARTIN JF, ERUSALIMSKY JD: Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. Synergistic interaction with hypoxia. Circulation 92:11-14, 1995
125. PERTOVAARA L, KAIPANEN A, MUSTONEN T, ET AL: Vascular endothelial growth factor is induced in response to transforming growth factor-β in fibroblastic and epithelial cells. J Biol Chem 269:6271-6274, 1994
126. DELLIAN M, WITWER BP, SALEHI HA, YUAN F, JAIN RK: Quantitation and physiological characterization of angiogenic vessels in mice. Effects of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and host microenvironment. Am J Pathol 149:59-71, 1996
127. YAMAGUCHI TP, DUMONT DJ, CONLON RA, BREITMAN ML, ROSSANT J: flk-1, an flt-related receptor tyrosine kinase is an early marker for endothelial cell precursors. Development 118:489-498, 1993
128. KHALIQ A, LI XF, SHAMS M, ET AL: Localisation of placenta growth factor (PIGF) in human term placenta. Growth Factors 13:243-250, 1996
129. VUORELA P, HATVA E, LYMBOUSSAKI A, ET AL: Expression of vascular endothelial growth factor and placenta growth factor in human placenta. Biol Reprod 56:489-494, 1997
130. KUZUYA M, SATAKE S, ESAKI T, ET AL: Induction of angiogenesis by smooth muscle cell-derived factor: Possible role in neovascularization in atherosclerotic plaque. J Cell Physiol 164:658-667, 1995
131. PLATE KH, RISAU W: Angiogenesis in malignant gliomas. Glia 15:339-447, 1995
132. ALBINI A, SOLDI R, GIUNCIUGLIO D, ET AL: The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells. Nature Med 2:1371-1375, 1996
133. FRANK S, HUBNER G, BREIER G, LONGAKER MT, GREENHALGH DG, WERNER S: Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J Biol Chem 270:12607-12613, 1995
134. CARMELIET P, COLLEN D: Insights into vascular biology via targeted gene inactivation and adenovirus-mediated gene transfer of the plasminogen system, in Coronary Restenosis. From Genetics to Therapeutics, edited by FEUERSTEIN GZ, New York, Marcel Dekker, Inc, 1997, pp 225-240
135. OKAMOTA N, TOBE T, HACKETT SF, ET AL: Transgenic mice with increased expression of vascular endothelial growth factor in the retina. Am J Pathol 151:281-291, 1997
136. CAO Y, LINDEN P, SHIMA D, BROWNE F, FOLKMAN J: In vivo angiogenic activity and hypoxia induction of heterodimers of placenta growth factor/vascular endothelial growth factor. J Clin Invest 98:2507-2511, 1996
137. VIGLIETTO G, MAGLIONE D, RAMBALDI M, ET AL: Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PIGF) associated with malignancy in human thyroid tumors and cell lines. 11:8, 1995
138. GLEADLE JM, EBERT BL, FIRTH JD, RATCLIFFE PJ: Regulation of angiogenic growth factor expression by hypoxia, transition metals and chelating agents. Am J Physiol 268:C1362-C1368, 1995
139. ENHOLM B, PAAVONEN K, RISTIMÄKI A, ET AL: Comparison of VEGF, VEGF-B, VEGF-C, Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene 14:2475-2483, 1997
140. WENGER RH, GASSMANN M: Oxygen(es) and the hypoxia-inducible factor-1. Biol Chem 378:609-616, 1997
141. SEMENZA GL: Transcriptional regulation by hypoxia-inducible factor-1. Trends Carciovasc Med 6:151-157, 1996
142. EMA M, TAYA S, YOKOTANI N, SOGAWA K, MATSUDA Y, FUJJIKURIYAMA Y: A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1 alpha regulates VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci USA 94:4273-4278, 1997
143. FLAMME I, FRÖHLICH T, VON REUTERN M, KAPPEL A, DAMERT A, RISAU W: HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1alpha and developmentally expressed in blood vessels. Mech Development 63:51-63, 1997
144. TIAN H, MCKNIGHT SL, RUSSELL DW: Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Devel 11:72-82, 1997
145. LEVY AP, LEVY NS, ILIOPOULUS O, JIANG C, KAELIN WG, GOLDBERG MA: Regulation of vascular endothelial growth factor by hypoxia and its modulation by the von Hippel-Lindau tumor suppressor gene. Kidney Int 51:575-578, 1997
146. WOOD SM, GLEADLE JM, PUGH CQ, HANKINSON O, RATCLIFFE P: The role of the aryl hydrocarbon receptor nuclear transporter (ARNT) in hypoxic induction of gene expression. J Biol Chem 271:15117-15123, 1996
147. ISNER JM, PEICZECK A, SCHAINFIELD R, ET AL: Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 348:370-374, 1996
148. PEARLMAN JD, ET AL: Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis. Nature Med 1:1085-1089, 1995
149. LI J, BROWN LF, GROSSMAN JD, MORGAN JP, SIMONS M: VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am J Physiol 270:H1803-H1811, 1996
150. TUDER RM, FLOOK BE, VOELKEL NF: Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J Clin Invest 95:1798-1807, 1995
151. YANG R, THOMAS GR, BUNTING S, ET AL: Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J Cardiovasc Pharmacol 27:838-844, 1996
152. ASAHARA T, BAUTERS C, PASTORE C, ET AL: Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. Circulation 91:2793-2801, 1995
153. LINDNER V, REIDY MA: Expression of VEGF receptors in arteries after endothelial injury and lack of increased endothelial regrowth in response to VEGF. Arterioscler Thromb Vasc Biol 16:1399-1405, 1996
154. KOUREMBANAS S, MCQUILLAN LP, LEUNG GK, FALLER DV: Nitric-oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia. J Clin Invest 92:99-104, 1993
155. YUAN F, CHEN Y, DELLIAN M, SAFAHAKHSH N, FERRARA N, JAIN RK: Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 93:14765-14770, 1996
156. MILLAUER B, SHAWVER LK, PLATE KH, RISAU W, ULLRICH A: Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367:576-579, 1994
157. KIM KJ, LI B, WINER J, ET AL: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841-844, 1993
158. DISALVO J, BAYNE ML, CONN G, ET AL: Purification and characterization of a naturally occurring vascular endothelial growth factor placenta growth factor heterodimer. J Biol Chem 270:7717-7723, 1995
159. BIRKENHAGER R, SCHNEPPE B, ROCKL W, WILTING J, WEICH HA, MCCARTHY JE: Synthesis and physiological activity of heterodimers comprising different splice forms of vascular endothelial growth factor and placenta growth factor. Biochem J 316:703-707, 1996
160. PARK JE, CHEN HH, WINER J, HOUCK KA, FERRARA N: Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1but not to Flk-1/KDR. J Biol Chem 269:25646-25654, 1994
161. MAGLIONE D, GUERRIERO V, VIGLIETTO G, DELLI BOVI P, PERSICO MG: Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci USA 88:9267-9271, 1991
162. ZICHE M, MAGLIONE D, RIBATTI D, ET AL: Placenta growth factor-1 is chemotactic, mitogenic and angiogenic. Lab Invest 76:517-531, 1997
163. HATVA E, BOHLING T, JASSKELAINEN J, PERSICO MG, HALTIA M, ALITALO K: Vascular growth factors and receptors in capillary hemangioblastomas and hemangiopericytomas. Am J Pathol 148: 763-775, 1996
164. CAO Y, JI WR, ROSIN A, CAO Y: Placenta growth factor: Identification and characterization of a novel isoform generated by RNA alternative splicing. Biochem Biophys Res Commun 235:493-498, 1997
165. SAWANO A, TAKAHASHI T, YAMAGUCHI S, AONUMURA M, SHIBUYA M: Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor. Cell Growth Differ 7:213-21, 1996
166. HAUSER S, WEICH H: A heparin-binding form of placenta growth factor (PIGF-2) is expressed in human umbilical vein endothelial cells and in placenta. Growth Factors 9:259-268, 1993
167. CAO Y, CHEN H, ZHOU L, ET AL: Heterodimers of placenta growth factor/vascular endothelial growth factor: Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR. J Biol Chem 271:3154-3162, 1996
168. CAO Y, LINDEN P, SHIMA D, BROWNE F, FOLKMAN J: In vivo angiogenic activity and hypoxia induction of heterodimers of placenta growth factor/vascular endothelial growth factor. J Clin Invest 98:2507-2511, 1996
169. OLOFFSON B, PAJUSOLA K, KAIPAINEN A, ET AL: Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA 93:2576-2581, 1996
170. JOUKOV V, PAJUSOLA K, KAIPAINEN A, ET AL: A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 15:290-298, 1996
171. LEE J, GRAY A, YUAN J, LUOH SM, AVRAHAM H, WOOD WI: Vascular endothelial growth factor-related protein: A ligand and specific activator of the tyrosine kinase receptor Flt4. Proc Natl Acad Sci USA 93:1988-1992, 1996
172. KUKK E, LYMBOUSSAKI A, TAIRA S, ET AL: VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 122:3829-3837, 1996
173. JELTSCH M, KAPPAINEN AA, JOUKOV V, ET AL: Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276:1423-1425, 1997
174. ORLANDINI M, MARCONCINI L, FERRUZZI R, OLIVIERO S: Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family. Proc Natl Acad Sci USA 93:11675-11680, 1996 [corrected; erratum to be published]
175. YAMADA Y, NEZU J, SHIMANE M, HIRATE Y: Molecular cloning of a novel vascular endothelial growth factor, VEGF-D. Genomics 42: 483-488, 1997
176. DE VRIES C, ESCOBEDO JA, UENO H, HOUCK K, FERRARA N, WILLIAMS LT: The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255:989-991, 1992
177. QUINN TP, PETERS KG, DE VRIES C, FERRARA N, WILLIAMS LT: Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc Natl Acad Sci USA 90:7533-7537, 1993
178. GALLAND F, KARAMYSHEVA A, PEBUSOUE MJ, ET AL: The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor. Oncogene 8:1233-1240, 1993
179. SOKER S, FIDDER H, NEUFELD G, KLAGSBRUN M: Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain. J Biol Chem 271:5761-5767, 1996
180. WALTENBERGER J, CLAESSON WELSH L, SIEGBAHN A, SHIBUYA M, HELDIN CH: Different signal transaction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269:26988-26995, 1994
181. SEETHARAM L, GOTOH N, MARU Y, NEUFELD G, YAMAGUCHI S, SIIIIHIVA M: A unique signal transduclion from FET tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. Oncogene 10:135-147, 1995
182. DAVIS SMYTH T, CHEN H, PARK J, PRESTA LG, FERRARA N: The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade. EMBO J 15:4919-4927, 1996
183. SHALABY F, HO J, STANFORD WL, ET AL: A requirement for Flk-1 in primitive and definitive hematopoiesis and vasculogenesis. Cell 89: 981-990, 1997
184. MUSTONEN T, ALITALO K: Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol 129:895-898, 1995
185. SATO TN, QIN Y, KOZAK CA, AUDUS KL: Tie-1 and tie-2 define another class of putative receptor tyrosine kinase genes expressed in early embryonic vascular system. Proc Natl Acad Sci USA 90:9355-9358, 1993 [erratum: 90:12056, 1993]
186. DUMONT DJ, YAMAGUCHI TP, CONLON RA, ROSSANT J, BRETTMAN ML: tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors. Oncogene 7:1471-1480, 1992
187. DAVIS S, ALDRICH TH, JONES PF, ET AL: Isolation of angiopoietin-1, a
188. PARTANEN J, PURI M, SCHWARTZ L, FISCHER KD, BERNSTEIN A, ROSSANT J: Cell autonomous functions of the receptor tyrosine kinase TIE in a late phase of angiogenic capillary growth and endothelial cell survival during murine development. Development 122:3013-3021, 1996
189. SLAVIN J: Fibroblast growth factors: At the heart of angiogenesis. Cell Biol Int 19:431-444, 1995
190. FRIESEL RE, MACIAG T: Molecular mechanisms of angiogenesis: Fibroblast growth factor signal transduction. FASEB J 9:919-925, 1995
191. KLAGSBRUN M, DLUZ S: Smooth muscle cell and endothelial cell growth factors. Trends Cardiovasc Med 3:213-217, 1993
192. JACKSON A, TARANTINI F, GAMBLE S, FRIEDMAN S, MACIAG T: The release of fibroblast growth factor-1 from NIH3T3 cells in response to temperature involves the function of cystein residues. J Biol Chem 270:33-36, 1995
193. VLODAVSKY I, FOLKMAN J, SULLIVAN R, ET AL: Endothelial-derived basic fibroblast growth factor: Synthesis and deposition into subendothelial extracellular matrix. Proc Natl Acad Sci USA 84:2292-2296, 1987
194. GUMBINER BM: Cell adhesion: The molecular basis of tissue architecture and morphogenesis. Cell 84:345-357, 1996
195. HUGHES SE, CROSSMAN D, HALL PA: Expression of basic and acidic fibroblast growth factors and their receptors in normal and atherosclerotic human arteries. Cardiovasc Res 27:1214-1219, 1993
196. HEBERT JM, BASILICO C, GOLDFARB M, HAUB O, MARTIN GR: Isolation of cDNAs encoding four mouse FGF family members and characterization of their expression patterns during embryogenesis. Dev Biol 138:454-463, 1990
197. LECONTE I, FOX JC, BALDWIN HS, BUCK CA, SWAIN JL: Adenoviral mediated expression of antisense FGF RNA during murine development disrupts embryogenesis and vasculogenesis. Circulation 94: 1-11, 1996
198. DAVIS MG, ET AL: Intracrine and autocrine effects of basic fibroblast growth factor in vascular smooth muscle cells. J Mol Cell Cardiol 29:1061-1072, 1997
199. LINDNER V, REIDY M: Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci USA 88:3739-3743, 1991
200. FOLKMAN J, KLAGSBRUN M: Angiogenesis factors. Science 235:442-447, 1987
201. SCHAPER W: Control of coronary angiogenesis. Eur Heart J 16(Suppl C):66-68,1995
202. SCHAPER W, ITO WD: Molecular mechanisms of coronary collateral vessel growth. Circ Res 79:911-919, 1996
203. SIMONS M, WARE JA: Food for starving hearts. (comment) Nature Med 2:519-520, 1996
204. HARADA K, GROSSMAN W, FRIEDMAN M, ET AL: Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts. J Clin Invest 94:623-630, 1994
205. YANAGISAWA-MIWA A, ET AL: Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 257:1401-1403, 1992
206. NABEL EG, YANG ZY, PLAUTZ G, ET AL: Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo. Nature 362:844-846, 1993
207. GIORDANO FJ, PING P, MCKIRNAN MD, ET AL: Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. (see comments) Nature Med 2:534-539, 1996
208. RIFKIN DB: Cross-talk among proteases and matrix in the control of growth factor action. Fibrinolysis 11:3-9, 1996
209. ADACHI E, HOPKINSON I, HAYASHI T: Basement-membrane stromal relationships: Interactions between collagen fibrils and the lamina densa. Int Rev Cytol 173:73-156, 1997
210. AUMAILLEY M, WIEDEMANN H, MANN K, TIMPL R: Binding of nidogen and the laminin-nidogen complex to basement-membrane collagen type IV. Eur J Biochem 184:241-248, 1989
211. DZIADEK M: Role of laminin-nidogen complexes in basement membrane formation during embryonic development. Experientia 51:901-913, 1995
212. DZIADEK M, MITRANGAS K: Differences in the solubility and susceptibility to proteolytic degradation of basement membrane components in adult and embryonic tissues. J Anal 184:298-310, 1989
213. TOKIDA Y, ARATANI Y, MORITA A, KITAGAWA Y: Production of two variant laminin forms by endothelial cells and shift of their relative levels by angiogenic steroids. J Biol Chem 265:18123-18129, 1990
214. RONGISH BJ, HINCHMAN G, DOTY MK, BALDWIN HS, TOMANEK RJ: Relationship of the extracellular matrix to coronary neovascularization during development. J Mol Cell Cardiol 28:2203-2215, 1996
215. HYNES RO: Genetic analyses of cell-matrix interactions in development. Curr Opin Genet Dev 4:569-574, 1994
216. HAAS TA, PLOW EF: Integrin-ligand interactions: A year in review. Curr Opin Cell Biol 6:656-662, 1994
217. ADAMS JC, WATT FM: Regulation of development and differentiation by the extracellular matrix. Development 117:1183-1198, 1993
218. VERBEEK MM, WESTPHAL JR, RUITER DJ, DE WALL RM: T-lymphocyte adhesion to human brain pericytes is mediatd via very late antigen-4/vascular cell adhesion molecule-1 interactions. J Immunol 154:5876-5884, 1995
219. KREIDBERG JA, DONOVAN MJ, GOLDSTEIN SL, ET AL: Alpha 3 beta 1 integrin has a crucial role in kidney and lung organogenesis. Development 122:3537-3547, 1996
220. FELDING HABERMANN B, CHERESH DA: Vitronectin and its receptors. Curr Opin Cell Biol 5:864-868, 1993
221. BROOKS PC, CLARK RA, CHERESH DA: Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264:569-571, 1994
222. HAMMES HP, BROWNLEE M, JONCZYK A, SUTTER A, PREISSNER KT: Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nature Med 2:529-533, 1996
223. COLLEN D, LIJNEN HR: Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 78:3114-3124, 1991
224. VASSALLI JD, SAPPINO JD, BELIN D: The plasminogen activator plasmin system. J Clin Invest 88:1067-1072, 1991
225. WIMAN B: Plasminogen activator inhibitor 1 (PAI-1) in plasma: Its role in thrombotic disease. Thromb Haemost 74:71-76, 1995
226. SCHNEIDERMAN J, LOSKUTOFF DJ: Plasminogen activator inhibitors. Trends Cardiovasc Med 1:99-102, 1991
227. LAWRENCE DA, GINSBURG D: Plasminogen activator inhibitors, in Molecular Biology of Thrombosis and Hemostasis, edited by ROBERTS HR, HIGH KA, New York, Marcel Dekker, 1995, pp 517-543
228. BLASI F, CONESE M, MOLLER LB, ET AL: The urokinase receptor: Structure, regulation and inhibitor-mediated internalization. Fibrinolysis 8:182-188, 1994
229. CHAPMAN HA JR, STONE OL: Co-operation between plasmin and elastase in elastin degradation by intact murine macrophages. Biochem J 222:721-728, 1984
230. CARMELIET P, MOONS L, LIJNEN R, ET AL: Urokinase-generated plasmin is a candidate activator of matrix metalloproteinases during atherosclerotic aneurysm formation. Nature Genet 17:439-446, 1997
231. MURPHY G: Matrix metalloproteinases and their inhibitors. Acta Orthop Scand 66(Suppl 256):55-60, 1995
232. DOLLERY CM, MCEWAN JR, HENNEY AM: Matrix metalloproteinases and cardiovascular disease. Circ Res 77:863-868, 1995
233. SIMPSON AJ, BOOTH NA, MOORE NR, BENNETT B: Distribution of plasminogen activator inhibitor (PAI-1) in tissues. J Clin Pathol 44:139-143, 1991
234. CLOWES AW, CLOWES MM, AU YP, REIDY MA, BELIN D: Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery. Circ Res 67:61-67, 1990
235. BACHARACH E, ITIN A, KESHET E: In vivo patterns of expression of urokinase and its inhibitor PAI-1 suggest a concerted role in regulating physiological angiogenesis. Proc Natl Acad Sci USA 89: 10686-10690, 1992
236. CARMELIET P, MOONS L, HERBERT J-M, ET AL: Urokinase-type but not tissue-type plasminogen activator mediates arterial neointima formation in mice. Circ Res 81:829-839, 1997
237. FEARNS C, SAMAD F, LOSKUTOFF DJ: Synthesis and localization of PAI-1 in the vessel wall, in Advances in Vascular Biology, edited by VAN HINSBERGH VWM. Camberwell, Australia, Gordon and Breach Publishers, 1996, pp 207-227
238. CARMELIET P, MOONS L, LIJNEN R, ET AL: Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation. A gene targeting and gene transfer study in mice. Circulation 96:3180-3191, 1997
239. PEPPER MS, SAPPINO AP, MONTESANO R, ORCI L, VASSALLI J-D: Plasminogen activator inhibitor-1 is induced in migrating endothelial cells. J Cell Physiol 153:129-139, 1992
240. PEPPER MS, FERRARA N, ORCI L, MONTESANO R: Vascular endothelial growth factor induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Comm 181:902-906, 1991
241. PEPPER MS, FERRARA N, ORCI L, MONTESANO R: Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Comm 189:824-831, 1992
242. CARMELIET P, KIECKENS L, SCHOONJANS L, ET AL: Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. J Clin Invest 92:2746-2755, 1993
243. CARMELIET P, STASSEN JM, SCHOONJANS L, ET AL: Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis and thrombolysis. J Clin Invest 92:2756-2760, 1993
244. DEWERCHIN M, NUFFELES AV, WALLAYS G, ET AL: Generation and characterization of urokinase receptor-deficient mice. J Clin Invest 97:870-878, 1996
245. CARMELIET P, MOONS L, ET AL: Receptor-independent role of urokinase-type plasminogen activator in arterial wound healing and intima formation in mice. J Cell Biol (in press)
246. CARMELIET P, MOONS L, PLOPLIS V, PLOW EF, COLLEN D: Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J Clin Invest 99:200-208, 1997
247. PLOPLIS VA, CARMELIET P, VAZIRZADEH S, ET AL: Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation 92:2585-2593, 1995
248. NOTHNICK WB, SOLOWAY P, CURRY TE: Assessment of the role of tissue inhibitor of metalloproteinase-1 (TIMP-1) during the preovulatory period in female mice lacking a functional TIMP-1 gene. Biol Reprod 56:1181-1188, 1997
249. MUDGETT JS, HUTHCHINSON NI, CHARTRAIN NA, ET AL: Stromelysin-1 deficient mice and collagen induced athritis susceptibility. Arthritis Rheum (in press)
250. SHIPLEY JM, WESSELSCHMIDT RL, KOBAYASHI DK, LEY TJ, SHAPIRO SD: Metalloelastase is required for macrophage-mediated proleolysis and matrix invasion in mice. Proc Natl Acad Sci USA 93:3942-3946, 1996
251. SABAPATHY KT, PEPPER MS, KIEFER F, ET AL: Polyoma middle-T induced vascular tumor formation: The role of the plasminogen activator/plasmin system. J Cell Biol 137:953-963, 1997
252. CAO Y, JI RW, DAVIDSON D, ET AL: Kringle domains of human angiostatin: Characterization of the anti-proliferative acitivty on endothelial cells. J Biol Chem 271:29461-19467, 1996
253. HOLMGREN L, O'REILLY MS, FOLKMAN J: Dormancy of metastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 1:149-153, 1995
254. BREVARIO F, CAVEDA L, CORADA M, ET AL: Functional properties of human vascular endothelial cadherin (7B4/cadherin-5), an endothelium-specific cadherin. Arterioscl Thromb Vasc Biol 15:1229-1239, 1995
255. VITOLO D, PARADISO P, UCCINI S, RUCO LP, BARONI CD: Expression of adhesion molecules and extracellular matrix proteins in glioblastomas: Relation to angiogenesis and spread. Histopathology 28:521-528, 1996
256. RABIET M-J, PLANTIER J-L, RIVAL Y, GINOUX Y, LAMPUGNANI M-G, DEJANA E: Thrombin-induced increase in endothelial permeability is associated with changes in cell-to-cell junction organization. Arterioscler Thromb Vasc Biol 16:488-496, 1996
257. BREIER G, BREVIARIO F, CAVEDA L, ET AL: Molecular cloning and expression of murine vascular endothelial-cadherin in early stage development of cardiovascular system. Blood 87:630-641, 1996
258. KATOH Y, PERIASAMY M: Growth and differentiation of smooth muscle cells during vascular development. Trends Cardiovasc Med 6:100-106, 1996
259. HIRSCHI KK, D'AMORE PA: Pericytes in the microvasculature. Cardiovasc Res 32:687-698, 1996
260. OWENS GK: Regulation of differentiation of vascular smooth muscle cells. Physiol Rev 75:487-517, 1995
261. SHEPRO D, MOREL NML: Pericyte physiology. FASEB J 7:1031-1038, 1993
262. SIMS DE: Recent advances in pericyte biology - Implications for health and disease. Can J Cardiol 7:431-443, 1991
263. DIAZ-FLORES L, GUTIERREZ R, VARELA H, RANCEL N, VALLADARES F: Microvascular pericytes: A review of their morphological and functional characteristics. Histol Histopathol 6:269-286, 1991
264. LITTLE TL, BEYER EC, DULING BR: Connexin 43 and connexin 40 gap junctional proteins are present in arteriolar smooth muscle and endothelium in vivo. Am J Physiol 268:H729-H739, 1995
265. KRAUSE D, KUNZ J, DERMIETZEL R: Cerebral Pericytes - A Second Line of Defense in Controlling Blood-Brain Barrier Peptide Metabolism. New York, Plenum Press, 1992
266. NEHLS V, DENZER K, DRENCKHAHN D: Pericyte involvement in capillary sprouting during angiogenesis in situ. Cell Tissue Res 270:469-474, 1992
267. PETERS A, JOSEPHSON K, VINCENT SL: Effects of aging on the neuroglial cells and pericytes within area 17 of the rhesus monkey cerebral cortex. Anat Rec 229:384-398, 1991
268. RHODIN JAG, FUGITA H: Capillary growth in the mesentery of normal young rats. Intravital video and electron microscope analyses. J Submicrosc Cytol Pathol 21:1-34, 1989
269. SIMS DE, MILLER FN, DONALD A, PERRICONE MA: Ultrastructure of pericytes in early stages of histamine-induced inflammation. J Morphol 206:333-342, 1990
270. IMAYAMA S, URABE H: Pericytes on the dermal microvasculature of the rat skin. Anat Embryol 169:271-274, 1984
271. CROCKER DJ, MURAD TM, GEER JC: Role of pericytes in wound healing. An ultrastructural study. Exp Mol Pathol 13:51-65, 1970
272. NAKAMURA H: Electron microscopic study of the prenatal development of the thoracic aorta in the rat. Am J Anat 181:406-418, 1988
273. JOSTEREAU FV, LEDOUARIN NM: The developmental relationship between osteocytes and osteoclasts: A study using the quail-chick nuclear marker in endochondral ossification. Dev Biol 63:253-265, 1978
274. AUSPRUNK DH, FOLKMAN J: Migration and proliferation of endothetial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res 14:53-65, 1977
275. NEHLS V, SCHUCHARDT E, DRENCKHAHN D: The effect of fibroblasts, vascular smooth muscle cells, and pericytes on sprout formation of endothelial cells in a fibrin gel angiogenesis system. Microvasc Res 48:349-363, 1994
276. ZERWES HG, RISAU W: Polarized secretion of platelet-derived growth factor-like chemotactic factor by endothelial cesll in vitro. J Cell Biol 105:2037-2041, 1987
277. HOLMGREN L, GLASER A, PFEIFER-OHLSSON S, OHLSSON R: Angiogenesis during human extraembryonic development involves th spatiotemporal control of the PDGF ligand and receptor gene expression. Development 113:749-754, 1991
278. MARMUR JD, ROSSIKHINA M, GUHA A, ET AL: Tissue factor is rapidly induced in arterial smooth muscle after balloon injury. J Clin Invest 91:2253-2259, 1993
279. DAVIS EC: Elastic lamina growth in the developing mouse aorta. J Histochem Cytochem 43:1115-1123, 1995
280. GLAGOV S, WEISENBERG E, ZARINS CK, STANKUNAVICIUS R, KOLETTIS GJ: Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 316:1371-1375, 1987
281. FUSTER V: Mechanisms leading to myocardial infarction: Insights from studies of vascular biology. Circulation 90:2126-2146, 1994
282. COWAN DB, LANGILLE BL: Cellular and molecular biology of vascular remodeling. Curr Opin Lipidol 7:94-100, 1996
283. GIBBONS GH, DZAU VJ: The emerging concept of vascular remodeling. N Engl J Med 330:1431-1438, 1994
284. POST MJ, BORST C, PASTERKAMP G, HAUDENSCHILD CC: Arterial remodeling in atherosclerosis and restenosis: A vague concept of a distinct phenomenon. Atherosclerosis 118:115-123, 1995
285. SHI Y, PIENIEK M, FARD A, O'BRIEN J, MANNION JD, ZALEWSKI A: Adventitial remodeling after coronary arterial injury. Circulation 93:340-348, 1996
286. KAKUTA T, CURRIER JW, HAUDENSCHILD CC, RYAN TJ, FAXON DP: Differences in compensatory vessel enlargement, not intimal formation, account for restenosis after angioplasty in the hypercholesterolemic rabbit model. Circulation 89:2809-2815, 1994
287. Ross R: The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 362:2844-2850, 1993
288. LIBBY P, SCHWARTZ D, BROGI E, TANAKA H, CLINTON SK: A cascade model for restenosis. A special case of atherosclerosis progression. Circulation 86:11147-11152, 1992
289. VIKKULA M, BOON LM, CARRAWAY KLR, ET AL: Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell 87:1181-1190, 1996
290. DUMONT DJ, GRADWOHL G, FONG GH, ET AL: Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev 8:1897-1909, 1994
291. KINGSLEY DM: The TGF-beta superfamily: New members, new receptors, and new genetic tests of function in different organisms. Genes Dev 8:133-146, 1994
292. AKHURST RJ, LEHNERT SA, FAISSNER A, DUFFIE E: TGF beta in murine morphogenetic processes: the early embryo and cardiogenesis. Development 108:645-656, 1990
293. PEPPER MS: Transforming growth factor-beta: vasculogenesis, angiogenesis and vessel wall integrity. Cytokine Growth Factor Res 8:21-43, 1997
294. PEPPER MS, VASSALLI JD, ORCI L, MONTESANO R: Biphasic effects of transforming growth factor-beta 1 on in vitro angiogenesis. Exp Cell Res 204:356-363, 1993
295. IRUELA-ARISPE ML, SAGE EH: Endothelial cells exhibiting angiogenesis in vitro proliferate in response to TFG-beta1. J Cell Biochem 52:414-430, 1993
296. KOH GY, KIM SJ, KLUG MG, PARK K, SOONPAA MH, FIELD LJ: Targeted expression of transforming growth factor-β1 in intracardiac grafts promotes vascular endothelial cell DNA synthesis. J Clin Invest 95:114-121, 1995
297. ANTONELLI ORLIDGE A, SAUNDERS KB, SMITH SR, D'AMORE PA: An activated form of transforming growth factor beta is produced by cocultures of endothelial cells and pericytes. Proc Natl Acad Sci USA 86:4544-4548, 1989
298. D'AMORE PA, SMITH SR: Growth factor effects on cells of the vascular wall: A survey. Growth Factors 8:61-75, 1993
299. METCALFE JC, GRAINGER DJ: TGF-β: Implications for vascular disease. J Hum Hypertens 9:679-683, 1995
300. NABEL EG, SHUM L, POMPILI VJ, ET AL: Direct transfer of transforming growth factor beta 1 gene into arteries stimulates fibrocellular hyperplasia. Proc Natl Acad Sci USA 90:10759-10763, 1993
301. KANAZAKI T, TAMURA K, TAKAHASHI K, ET AL: In vivo effect of TGF-β1: Enhanced intimal thickening by administration of TGF-β1 in rabbit arteries injured with a balloon catheter. Arterioscl Thromb Vasc Biol 15:1951-1957, 1995
302. MAJESKY MW, LINDNER V, TWARDZIK DR, SCHWARTZ SM, REIDY MA: Production of transforming growth factor β1 during repair of arterial injury. J Clin Invest 88:904-910, 1991
303. WOLF YG, RASMUSSEN LM, RUOSLAHTI E: Antibodies against transforming growth factor-β1 suppress intimal hyperplasia in a rat model. J Clin Invest 93:1172-1178, 1994
304. BATTEGAY EJ, RAINES EW, SEIFERT A, BOWEN-POPE DF, ROSS R: TGF-β induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell 63:515-524, 1990
305. STOUFFER GA, OWENS GK: TGF-β promotes proliferation of cultured smooth muscle cells via both PDGF-AA-dependent and PDGF-AA-independent mechanisms. J Clin Invest 93:2048-2055, 1994
306. OSHIMA M, OSHIMA H, TAKETO MM: TGF-beta receptor type 11 deficiency results in detects of yolk sac hematopoiesis and vasculogenesis. Dev Biol 179:297-302, 1996
307. MCALLISTER KA, GROGG KM, JOHNSON DW, ET AL: Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nature Genet 8:345-351, 1994
308. ROSS R, RAINES EW, BOWEN POPE DF: The biology of platelet-derived growth factor. Cell 46:155-169, 1986
309. HELDIN CH, WESTERMARK B: Platelet-derived growth factor: Three isoforms and two receptor types. Trends Genet 5:108-111, 1989
310. RISAU W, DREXLER H, MIRONOV V, ET AL: Platelet-derived growth factor is angiogenic in vivo. Growth Factors 7:261-266, 1992
311. MARTINS RN, CHLEBOUN JO, SELLERS P, SLEIGH M, MUIR J: The role of PDGF-BB on the development of the collateral circulation after acute arterial occlusion. Growth Factors 10:299-306, 1994
312. BROWN DM, HONG SP, FARRELL CL, PIERCE GF, KHOURI RK: Platelet-derived growth factor BB induces functional vascular anastomoses in vivo. Proc Natl Acad Sci USA 92:5920-5924, 1995
313. LINDNER V, REIDY MA: Platelet-derived growth factor ligand and receptor expression by large vessel endothelium in vivo. Am J Pathol 146:1488-1497, 1995
314. BATTEGAY EJ, RUPP J, IRUELA ARISPE L, SAGE EH, PECH M: PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF beta-receptors. J Cell Biol 125:917-928, 1994
315. GROTENDORST GR, CHANG T, SEPPA HE, KLEINMAN HK, MARTIN GR: Platelet-derived growth factor is a chemoattractant for vascular smooth muscle cells. J Cell Physiol 113:261-266, 1982
316. CORJAY MH, THOMPSON MM, LYNCH KR, OWENS GK: Differential effect of platelet-derived growth factor versus serum-induced growth on smooth muscle alpha-actin and nonmuscle β-actin mRNA expression in cultured rat aortic smooth muscle cells. J Biol Chem 264: 10501-10506, 1989
317. JAWIEN A, BOWEN-POPE DF, LINDNER V, SCHWARTZ SM, CLOWES AW: Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest 89:507-511, 1992
318. NABEL, EG, PLAUTZ GE, NABEL GJ: Recombinant growth factor gene expression in vascular cells in vivo. Ann N Y Acad Sci 714:247-252, 1994
319. FERNS GAA, RAINES EW, SPRUGEL KH, MOTANI AS, REIDY MA, ROSS R: Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 253:1129-1132, 1991
320. SIROIS MG, SIMONS M, EDELMAN ER: Antisense oligonucleotide inhibition of PDGFR-β subunit expression directs suprresion of intimal thickening. Circulation 95:669-676, 1997
321. ALPERS CE, SEIFERT RA, HUDKINS KL, JOHNSON RJ, BOWEN-POPE DF: Developmental patterns of PDGFB-chain, PDGF receptor and alpha-actin expression in human glomerulonogenesis. Kidney Int 42:390-399, 1992
322. SORIANO P: Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice. Genes Dev 8:1888-1896, 1994
323. SCHATTEMAN GC, MOTLEY ST, EFFMAN EL, BOWEN-POPE DF: Platelet-derived growth factor receptor alpha subunit deleted patch mouse exhibits severe cardiovascular dysmorphogenesis. Teratology 51:351-366, 1995
324. MACSWEENEY ST, POWELL JT, GREENHALGH RM: Pathogenesis of abdominal aortic aneurysm. Br J Surg 81:935-941, 1994
325. HALLORAN BG, BAXTER BT: Pathogenesis of aneurysms. Semin Vasc Surg 8:85-92, 1995
326. ANIDJAR S, KIEFFER E: Pathogenesis of acquired aneurysms of the abdominal aorta. Ann Vasc Surg 6:298-305, 1992
327. PATEL MI, HARDMAN DT, FISHER CM, APPLEBERG M: Current views on the pathogenesis of abdominal aortic aneurysms. J Am Coll Surg 181:371-382, 1995
328. LÖHLER J, TIMPL R, JAENISCH R: Embryonic lethal mutation in mouse collagen I gene causes rupture of blood vessels and is associated with erythropoietic and mesenchymal cell death. Cell 38:597-607, 1984
329. PROCKOP DJ: Collagens: Molecular biology, disease, and potentials for therapy. Annu Rev Biochem 64:403-434, 1995
330. LIU X, WU H, BYRNE M, KRANE S, JAENISCH R: Type III collagen is crucial for collagen 1 fibrillogenesis and for normal cardiovascular development. Proc Natl Acad Sci USA 94:1852-1856, 1997
331. ANDRIKOPOULOS K, LIU X, KEENE DR, JAENISCH R, RAMIREZ F: Targeted mutation in the col5a2 gene reveals a regulatory role for type V collagen during matrix assembly. Nature Genetics 9:31-36, 1995
332. CURRAN ME, ATKINSON DL, EWART AK, MORRIS CA, LEPPERT MF, KEATING MT: The elastin gene is disrupted by a translocation associated with supravalvular aortic stenosis. Cell 73:159-168, 1993
333. EWART AK, JIN W, ATKINSON DL, MORRIS CA, KEATING MT: Supravalvular aortic stenosis associated with a deletion disrupting the elastin gene. J Clin Invest 93:1071-1077, 1994
334. KOYAMA H, RAINES EW, BORNFEDT KE, ROBERTS JM, ROSS R: Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of cdk2 inhibitor. Cell 87:1069-1078, 1996
335. ZHANG H, HU W, RAMIREZ F: Developmental expression of fibrillin genes suggests heterogeneity of extracellular microfibrils. J Cell Biol 129:1165-1176, 1995
336. RANTAMÄKI T, KARTTUNEN L, PELTONEN L: Badly engineered fibrillin. Lessons from molecular studies of Marfan syndrome. Trends Cardiovasc Med 7:282-288, 1997
337. PEREIRA L, ANDRIKOPOULOS K, TIAN J, ET AL: Targetting of the gene encoding fibrillin-1 recapitulates the vascular aspect of Marfan syndrome. Nature Genet 17:218-222, 1997
338. PUTNAM EA, ZHANG H, RAMIREZ F, MILEWICZ DM: Fibrillin-2 (FBN2) mutations result in the Marfan-like disorder, congenital contractural arachnodactyly. Nature Genet 11:456-458, 1995
339. EDGINGTON TS, MACKMAN N, BRAND K, RUF W: The structural biology of expression and function of tissue factor. Thromb Haemost 66:67-79, 1991
340. CAMERER E, KOSTO AB, PRYDZ H: Cell biology of tissue factor, the principal initiator of blood coagulation. Thromb Res 81:1-41, 1996
341. PETERSEN LC, VALENTIN S, HEDNER U: Regulation of the extrinsic pathway system in health and disease: The role of factor VIIa and tissue factor pathway inhibitor. Thromb Res 79:1-47, 1995
342. DAVIE EW: Biochemical and molecular aspects of the coagulation cascade. Thromb Haemost 74:1-6, 1995
343. BROZE GJ JR: Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med 46:103-112, 1995
344. ESMON CT: The protein C anticoagulant pathway. Arterioscler Thromb 12:135-145, 1992
345. ALTIERI DC: Xa receptor EPR-1. FASEB J 9:860-865, 1995
346. CONTRINO J, HAIR G, KREUTZER DL, RICKLES FR: In situ detection of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast disease. (see comments) Nature Med 2:209-215, 1996
347. SOIFER SJ, PETERS KG, O'KEEFE J, COUGHLIN SR: Disparate temporal expression of the prothrombin and thrombin receptor genes during mouse development. Am J Pathol 144:60-69, 1994
348. LUTHER T, FLOSSEL C, MACKMAN N, ET AL: Tissue factor expression during human and mouse development. Am J Pathol 149:101-113, 1996
349. BUGGE TH, XIAO Q, KOMBRINCK KW, ET AL: Fatal embryonic bleeding events in mice lacking tissue factor, the cell-associated initiator of blood coagulation. Proc Natl Acad Sci USA 93:6258-6263, 1996
350. TOOMEY JR, KRATZER KE, LASKY NM, STANTON JJ, BROZE GJ JR: Targeted disruption of the murine tissue factor gene results in embryonic lethality. Blood 88:1583-1587, 1996
351. TOOMEY JR, KRATZER KE, LASKY NM, BROZE GJJ: Effect of tissue factor deficiency on mouse and tumor development. Proc Natl Acad Sci USA 94:6922-6926, 1997
352. ROSEN E, CHAN JY, ESOHE I, ET AL: Factor VII deficient mice develop normally but suffer fatal perinatal bleeding. Nature 390:290-294, 1997
353. GASIC GP, ARENAS CP, GASIC TB, GASIC GJ: Coagulation factors X, Xa, and protein S as potent mitogens of cultured aortic smooth muscle cells. Proc Natl Acad Sci USA 89:2317-23120, 1992
354. CONNOLLY AJ, ISHIHARA H, KAHN ML, FARESE RV JR, COUGHLIN SR: Role of the thrombin receptor in development and evidence for a second receptor. Nature 381:516-519, 1996
355. CUI J, O'SHEA KS, PURKAYASTHA A, SAUNDERS TL, GINSBURG D: Fatal haemorrhage and incomplete block to embryogenesis in mice lacking coagulation factor V. Nature 384:66-68, 1996
356. SUH TT, HOLMBACK K, JENSEN NJ, ET AL: Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev 9:2020-2033, 1995
357. ETTELAIE C, JAMES NJ, WILBOURN B, ADAM JM, NASEEM KM, BRUCKDORFER KR: The mechanism of inhibition of factor III (tissue factor) activity by apolipoprotein B-100L protein-protein interactions. Arterioscler Thromb Vasc Biol 16:639-645, 1996
358. FAN Z, LARSON PJ, BOGNAGKI J, ET AL: Tissue factor regulates plasminogen binding and activation. Blood (in press)
359. HUANG ZF, HIGUCHI D, LASKY N, BROZE GJJ: Tissue factor pathway inhibitor gene disruption produces intrauterine lehtality in mice. Blood 90:944-951, 1997
360. ISHIHARA H, CONNOLLY AJ, ZENG D, ET AL: Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 386:502-506, 1997
361. DARROW AL, FUNG-LEUNG WP, YE RD, ET AL: Biological consequences of thrombin receptor deficiency in mice. Thromb Haemost 76:860-866, 1996
362. HEALY AM, RAYBURN HB, ROSENBURG RD, WEILER H: Absence of the blood-clotting regulator thrombomodulin causes embryonic lethality in mice before development of a functional cardiovascular system. Proc Natl Acad Sci USA 92:850-854, 1995
363. SHIVDASANI RA, ET AL: Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/ MGDF in megakaryocyte development. Cell 81:695-704, 1995
364. BI L, LAWLER AM, ANTONARAKIS SE, HIGH KA, GEARHART JD, KAZAZIAN HH JR: Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nature Genet 10:119-121, 1995
365. CLOWES AW, REIDY MA: Prevention of stenosis after vascular reconstruction: Pharmacologic control of intimal hyperplasia - A review. J Vasc Surg 13:885-891, 1991
366. SCHWARTZ SM, REIDY MA, O'BRIEN ER: Assessment of factors important in atherosclerotic occlusion and restenosis. Thromb Haemost 74:541-551, 1995
367. VAN LEEUWEN RT: Extracellular proteolysis and the migrating vascular smooth muscle cell. Fibrinolysis 10:59-74, 1996
368. REIDY MA, IRVIN C, LINDNER V: Migration of arterial wall cells. Expression of plasminogen activators and inhibitors in injured rat arteries. Circ Res 78:405-414, 1996
369. NEWMAN KM, JEAN CLAVDE J, LI H, ET AL: Cellular localization of matrix metalloproteinases in the abdominal aortic aneurysm wall. J Vasc Surg 20:814-820, 1994
370. GALIS ZS, SUKHOVA GK, KRANZHÖFER R, CLARK S, LIBBY P: Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci USA 92:402-406, 1995
371. GALIS ZS, MUSZYNSKI M, SUKHOVA GK, ET AL: Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res 75:181-189, 1994
372. HALPERT I, SIRES UI, ROUY JD, ET AL: Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc Natl Acad Sci USA 93:9748-9753, 1996
373. IRIZARRY E, NEWMAN KM, GANDHI RH, ET AL: Demonstration of interstitial collagenase in abdominal aortic aneurysm disease. J Surg Res 54:571-574, 1993
374. SAKALIBASAN N, DELVENNE P, NUSGENS BV, LIMET R, LAPIERE CM CM: Activated forms of MMP2 and MMP9 in abdominal aortic aneurysms. J Vasc Surg 24:127-133, 1996
375. CARMELIET P, MOONS L, STASSEN JM, ET AL: A model for arterial neointima formation using perivascular electric injury in mice. Am J Pathol 150:761-777, 1997
376. HERBERT JM, LAMARCHE I, CARMELIET P: Urokinase- and tissue-type plasminogen activator are required for the mitogenic and chemotactic effects of bovine fibroblast growth factor and platelet-derived growth factor-BB for vascular smooth muscle cells. J Biol Chem 272:23585-23591, 1997
377. LIJNEN R, VAN HOEF B, LUPE F, MOONS L, CARMELIET P, COLLEN D: Plasminogen/plasmin and matrix metalloproteinase system function after vascular injury in mice with targeted inactivation of fibrinolytic genes. Arterioscl Thromb Vasc Biol (in press)
378. LUCAS A, LIU L, MACEN J, ET AL: Virus-encoded serine proteinase inhibitor SERP-1 inhibits atherosclerotic plaque development after balloon angioplasty. Circulation 94:2890-2900, 1996
379. SHI C, RUSSELL ME, BIANCHI C, NEWELL JB, HABER E: Murine model of accelerated transplant arteriosclerosis. Circ Res 75:199-207, 1994
380. PLOPLIS V, FRENCH E, CARMELEIT P, COLLEN D, PLOW E: The plasminogen system and cell migration during an inflammatory response. (abstract) Fibrinolysis 10:55, 1996
381. BELKIN M, DONALDSON MC, WHITTEMORE AD: Abdominal aortic aneurysms. Curr Opin Cardiol 9:581-590, 1994
382. ERNST CB: Abdominal aortic aneurysm. N Engl J Med 328:1167-1172, 1993
383. JUHAN-VAGUE I, COLLEN D: On the role of coagulation and fibrinolysis in atherosclerosis. Ann Epidemiol 2:427-438, 1992
384. HAMSTEN A, ERIKSSON P: Fibrinolysis and atherosclerosis: An update. Fibrinolysis 8:253-262, 1994
385. SCHNEIDERMAN J, SAWDEY MS, KEETON MR, ET AL: Increased type I plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 89:6998-7002, 1992
386. HAMSTEN A, DE FAIRE U, WALLDIUS G, ET AL: Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 2:3-9, 1987
387. SCHNEIDERMAN J, BORDIN GM, ENGELBERG I, ET AL: Expression of fibrinolytic
388. LUPU F, HEIM DA, BACHMANN F, HURNI M, KAKKAR VV, KRUITHOF EK: Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol 15:1444-1455, 1995
389. PLUMP AS, SMITH JD, HAYEK T, ET AL: Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71:343-353, 1992
390. XIAO Q, DANTON MJS, WITTE DP, ET AL: Plasminogen deficiency accelerates vessel wall disease in mice predisposed to atherosclerosis. Proc Natl Acad Sci USA 94:10335-10340, 1997
391. CHAPMAN HA JR, STONE OL, VAVRIN Z: Degradation of fibrin and elastin by intact human alveolar macrophages in vitro. Characterization of a plasminogen activator and its role in matrix degradation. J Clin Invest 73:806-815, 1984
392. LIBBY P: Molecular basis of the acute coronary syndromes. Circulation 91:2844-2850, 1995